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Background: Mutations in the POLG1 gene have variable phenotypic presentations and a high degree of clinical
suspicion is necessary for their recognition. Parkinsonism and ataxia are the most common movement disorders
associated with POLG1 mutations but no phenotype-genotype correlation has been established.
Case presentation: We identified a male patient with progressive external ophthalmoplegia who also developed a
progressive bradykinesia, rigidity and camptocormia in the third decade. Parkinsonism was partially responsive to
dopaminegic replacement. His father and brother had reportedly similar clinical problems. Genetic analysis
identified a novel mutation p.K512M in the POLG1 gene.
Conclusion: This report further expands the spectrum of POLG1-associated neurologic problems with the report of
a novel mutation in the linker region of the gene, which are rarely associated with parkinsonism.
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Mitochondrial DNA polymerase gamma (POLG1) is a
nuclear-encoded protein critical for the synthesis, repli-
cation and repair of mitochondrial DNA (mtDNA). Ab-
normal function of this sole mtDNA polymerase leads to
defective oxidative phosphorylation and ATP production.
Impaired integrity of mtDNA with its depletion or dele-
tion causes a broad spectrum of both non-neurological
and neurological phenotypes [1]. Greater than one
hundred pathogenic mutations in this enzyme have been
found since it was first described [2]. These include, but
are not limited to parkinsonism, chronic progressive
external ophthalmoplegia (CPEO), cerebellar ataxia, sen-
sory polyneuropathy, Alpers-Huttenlocher syndrome,
which is characterized by progressive encephalopathy with
seizures and hepatic failure, isolated myoclonic epilepsy or
non-syndromic liver failure. [2-6] This wide variety of
distinct and seemingly unrelated clinical problems with
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reproduction in any medium, provided the orinheritance presents a significant challenge to clinicians
and a high degree of clinical suspicion is typically crucial
for the recognition of the underlying genetic mechanism.
Here we report a novel mutation in POLG1 located in the
linker domain of this gene in a patient with parkinsonism
and CPEO.
Case presentation
Presented patient is a 79-year old Caucasian who deve-
loped first neurologic problems in his thirties with
bilateral ptosis and double vision. The ophthalmologic
examination showed a progressive ophthalmoplegia and
he required several corrective eyelid surgeries to mitigate
his ptosis. Shortly thereafter, he developed a shuffling
gait and overall slowness of movements. He experienced
a gradual progression of his rigidity, bradykinesia with-
out any significant asymmetry, hypophonia and within
10–15 years he also developed camptocormia with sub-
sequent postural instability (Additional file 1).
Parkinsonism was partially responsive to dopaminergic
replacement with carbidopa/levodopa with the highest
used dose of 1250 mg per day. Later, amantadine at the
dose of 300 mg/day was added for his gait difficultiesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reduced because of hallucinations. Dementia, treated
with memantine and donepezil, was diagnosed at the age
of 75 years.
Family history was positive for external ophthalmople-
gia and Parkinson’s disease diagnosed in his father and
brother. We could not personally examine his brother
but available history indicated that he was diagnosed
with Parkinson’s disease and reported a good response
to 600 mg of levodopa per day.
We performed muscle biopsy because of suspicion for
a mitochondrial disorder at the age of 70 years. Muscle
biopsy obtained from the vastus lateralis muscle revealed
nonspecific changes with some irregularities of cyto-
chrome c-oxidase staining but ragged red fibers were
not seen. These changes alone were not sufficient for
the definite diagnosis of a mitochondrial myopathy. Re-
peat biopsy was considered with sampling of additional
muscles but the patient declined. Brain MRI showed
only mild scattered white matter abnormalities.
Sequencing of the POLG1 gene was done by Sanger se-
quencing. DNA extraction from blood was carried out
using standard procedures. All exons of the POLG1 gene
were amplified by PCR reaction with previously published
intron-based primers [7]. Bidirectional Sanger sequencing
was performed for each amplicon and detected single nu-
cleotide polymorphisms (SNP) were compared with avai-
lable public domain databases. We identified a novel
heterozygous p.K512M mutation (c.1535A>T) (Figure 1).
In silico analysis of this single nucleotide polymorphismFigure 1 Panel A shows c.1535A>T mutation (arrow) and panel
B normal sequence of the same segment.using PolyPhen-2 software (http://genetics.bwh.harvard.
edu/pph2) predicted that this change is possibly damaging
with a score of 0.906 (sensitivity 0.82 and specificity 0.94).
This is a highly conserved position in the linker region of
the POLG1 protein (Figure 2) and sequencing of 100
normal, ethnically matched control individuals did not
identify this sequence changes, further supporting its role
as a disease-causing mutation.
Mutations in the adenosine nucleotide translocator 1
(ANT1) and twinkle (C10ORF2) genes have also been
associated with CPEO and additional neurologic prob-
lems, including parkinsonism [8,9]. We also sequenced
all coding exons of these genes using the same approach
as for POLG1 analysis but no putative mutations were
identified.
Conclusions
The presented patient reflects a significant phenotypic
variability associated with mutations in the POLG1 gene.
Parkinsonism is relatively rare phenotype caused by muta-
tions in this gene. Previously suggested role of POLG1 va-
riants as a relatively common of idiopathic Parkinson
disease (PD) has not been replicated, even though it is of
interest because of evidence for mitochondrial dysfunction
in PD [10]. However, the specific combination of CPEO
and parkinsonism, which is partially responsive to dopa-
minergic therapy is occasionally seen in patients harboring
POLG1mutations. [4,6,11-13] Most cases with this clinical
phenotype carry heterozygous mutations in the polyme-
rase domain of the POLG1 gene and parkinsonism is a
variable and inconsistent feature in these patients [4-6].
Mutations in the linker region of the POLG1gene are less
common and limited data suggest that parkinsonism is
more severe feature in these patients. The detected muta-
tion p.K512M is the third known mutation in this func-
tional domain causing CPEO and parkinsonism, together
with the previously reported p.S511N and p.G517V muta-
tions. [7,14] We could not confirm the segregation of
p.K512M mutation with the disease within this small
kindred because no additional family members were avai-
lable for genetic analysis, but the lysine residue at theFigure 2 Alignment of the linker region of POLG1 protein with
highly conserved amino acid residues among multiple species.
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normal chromosomes did not identify this variant in a
normal population (Figure 2).
Similar phenotype of CPEO and parkinsonism can be
also caused by mutations in the (ANT1) and mitochondrial
DNA helicase twinkle genes [8,9]. These two genes were
excluded as a potential cause of in our patient, which fur-
ther strengthens the argument that the detected novel mu-
tation in POLG1 is indeed the disease-causing mutations.
We did not detect any definite signs of mitochondrial
skeletal muscle myopathy in spite of severe involvement of
extraocular muscles. However, other POLG1 patients with
neurologic involvement and negative muscle biopsy were
previously reported, suggesting that normal muscle biopsy
does not exclude POLG1 mutations as a cause of multi-
systemic neurologic involvement [15].
Mutations in the POLG1 gene have emerged as another
great imitator of various movement disorders and a high
index of suspicion is necessary for their correct identifica-
tion. Cerebellar ataxia is one of the most genetically he-
terogeneous movement disorders and genotype-phenotype
correlations are very unreliable and the rational algorithms
for the genetic testing are only emerging. A combination of
external ophthalmoplegia and/or polyneuropathy was
caused by POLG1 mutations in 80% of patients who tested
negatively for SCA1-3, and 6, and also did not have
molecular evidence for Friedreich ataxia [7,16]. One of the
most common mutations causing ataxia is p.A467T muta-
tion that is also located in the linker domain but it causes
neurologic disease only in a homozygous state. Further-
more, this mutation in a homozygous state is the most
common cause of Alpers-Huttenlocher syndrome [17].
The reasons for this variability in phenotype-genotype
correlation are unknown.
Parkinsonism associated with CPEO and cerebellar ataxia
associated with upgaze palsy and neuropathy are easily
recognizable syndromes where mutations in the POLG1
gene should be considered. It is also important in furthering
our understanding and research into the etiology of idio-
pathic Parkinson’s disease, particularly with regard to a pos-
sible contribution of mitochondrial dysfunction.Consent
Written informed consent was obtained from the patient
for publication of this case report and to publish the videos.
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